{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-020882","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.120572+00:00","generated_at":"2026-06-05T00:46:32.407465+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics FY2023 net loss from operations down 50% to $17.1M; stenoparib complete response in Phase 2","bullets":["Net loss from operations $17.1M in 2023 vs $34M in 2022 (down 50%); net loss $11.9M vs $16.1M.","R&D expenses $7.1M and G&A $10.0M both flat year-over-year; no product revenue reported.","Interim CEO Thomas Jensen appointed Dec 2023; former Eli Lilly exec Jeremy Graff named Executive Advisor.","Dec 2023 Phase 2 stenoparib data: 1 complete response, 4 stable disease in evaluable advanced ovarian cancer patients.","Expects interim Phase 2 stenoparib data in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-020882","json":"https://secwatch.observer/filing/0001213900-24-020882.json","markdown":"https://secwatch.observer/filing/0001213900-24-020882.md","text":"https://secwatch.observer/filing/0001213900-24-020882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/ea0201409-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:46:32.407465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7eae35e68e3a84a28524f8cb3c6deac9404bbc2d","claim":"Allarity Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $11.9 million.","evidence_excerpt":"Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$11.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}